---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-297554"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2026-07-07T20:38:54+00:00"
generated_at: "2026-07-07T20:40:04.407521+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharmaceuticals appoints Donn Casale as CEO, replacing Richard Lowenthal terminated without cause

## Summary
- Donn Casale, previously President, appointed CEO effective July 7, 2026.
- Richard Lowenthal terminated without cause on July 6, 2026.
- Casale also appointed to Board as Class III director until 2029 annual meeting.
- No details on compensation or transition provided in the filing.

## SEC filing metadata
- accession: 0001193125-26-297554
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2026-07-07T20:38:54+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/d157645d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-297554
- JSON: https://secwatch.observer/filing/0001193125-26-297554.json
- Plain text: https://secwatch.observer/filing/0001193125-26-297554.txt

## Key facts
- Executive change
  Donn Casale was appointed as Chief Executive Officer at ARS Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm
- Executive change
  Donn Casale was appointed as Class III director at ARS Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class III director
  source text: Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm
- Executive change
  Richard Lowenthal departed as Chief Executive Officer at ARS Pharmaceuticals, Inc..
  - Action: terminated without cause
  - Role: Chief Executive Officer
  source text: Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.